Aryl Hydrocarbon Receptor Modulation by Tuberculosis Drugs Impairs Host Defense and Treatment Outcomes
Andreas Puyskens(Max Planck Institute for Infection Biology), Pedro Moura‐Alves(University of Oxford), Stefan H. E. Kaufmann(Humboldt-Universität zu Berlin), Gang Pei(Tongji University), Marion Klemm(Max Planck Institute for Infection Biology), Marcel J. M. Schaaf(Leiden University), Gerd Krause(Leibniz-Forschungsinstitut für Molekulare Pharmakologie), Annika Kreuchwig(Bayer (Germany)), Krishnamoorthy Gopinath(Humboldt-Universität zu Berlin), Ute Guhlich‐Bornhof(Max Planck Institute for Infection Biology), Robert Hurwitz(University of Bonn), Anne Stinn(Universität Hamburg), Annemarie H. Meijer(Leiden University), Michiel van der Vaart(Leiden University), Jonas Protze(Leibniz-Forschungsinstitut für Molekulare Pharmakologie)
Cited by 48
Related Papers
IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases
|Nature|2014|1k
Nuclear cGAS suppresses DNA repair and promotes tumorigenesis
|Nature|2018|661
Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis
|Nature Medicine|2003|539
Expression analysis of the Toll-like receptor and TIR domain adaptor families of zebrafish
|Molecular Immunology|2003|519
β-Arrestin2 Is Critically Involved in CXCR4-mediated Chemotaxis, and This Is Mediated by Its Enhancement of p38 MAPK Activation
|Journal of Biological Chemistry|2002|381